CME High Suspicion, Better Outcomes: Evaluating Thrombotic Events for Underlying ET or PV Physicians: Maximum of 0.25 AMA PRA Category 1 Credit™

Activity

Claim Credit

BACK

|

NEXT

Introduction

Thrombosis in ET/PV

References

Introduction

In this module, Pankit Vachhani, MD, discusses the multifactorial pathogenesis, risk assessment, clinical impact, and management strategies of thrombotic events in myeloproliferative neoplasms (MPNs), including the role of hematologic abnormalities, JAK2 mutations, and evidence-based treatment approaches.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

BACK

|

NEXT

Resources

• PDF hangout

• PowerPoint

• Infographic

-->

Activity Claim Credit BACK | NEXT Introduction Thrombosis in ET/PV References Introduction In this module, Pankit Vachhani, MD, discusses the multifactorial pathogenesis, risk assessment, clinical impact, and management strategies of thrombotic events in myeloproliferative neoplasms (MPNs), including the role of hematologic abnormalities, JAK2 mutations, and evidence-based treatment approaches. The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. Before continuing with this educational activity, please take a moment to answer the following questions. BACK | NEXT Resources

• PDF hangout
• PowerPoint
• Infographic -->